Epibiotech CEO Sung Jong-hyeok said that through the presentation of the results of the non-clinical test conducted by the company, it was confirmed that the number of hairs increased by 40% and the hair thickness by 30% after 1 month after transplantation of human dermal papilla cells in pig skin. He also explained that the non-clinical toxicity test of EPI-001, a dermal papilla cell pipeline, was completed in June, and that it will apply for an IND in the second half of the year and enter the phase 1 clinical trial in 2023.
www.pharmnews.com
에피바이오텍-연세대 종합약학연구소,탈모 혁신신약 개발 심포지엄 성료 - 팜뉴스
탈모치료제 전문 연구개발 기업 에피바이오텍(대표 성종혁)이 연세대학교 종합약학연구소와 공동 주최한 '탈모 치료를 위한 혁신 약물 개발(Innovative drug
Last edited:
